Time and dose-dependent effects of Labisia pumila on the bone strength of postmenopausal osteoporosis rat model

详细信息    查看全文

• 作者：Nadia Mohd Effendy ; Shahrum Abdullah…
• 关键词：Osteoporosis ; Postmenopausal ; Estrogen ; Bone strength ; Biomechanical
• 刊名：BMC Complementary and Alternative Medicine
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：15
• 期：1
• 全文大小：1,647 KB
• 参考文献：1. Christiansen, C (1991) Consensus Development Conference: prophylaxis and treatment of osteoporosis. Am J Med 90: pp. 107-10 CrossRef
  2. Koh, LK, Saw, SM, Lee, JJ, Leong, KH, Lee, J (2001) Hip fractures incidence rates in Singapore 1991-998. Osteoporos Int 12: pp. 311-8 CrossRef
  3. Cummings, SR, Melton, LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359: pp. 1761-7 CrossRef
  4. Melton, LJ (2000) Who has osteoporosis? A conflict between clinical and public health perspectives. J Bone Miner Res 15: pp. 2309 CrossRef
  5. Henrik, GA, Bj?rn, ER, Teppo, LNJ, Cecilia, R, Jan-Ake, N, Ingemar, S (2010) Prevalence of osteoporosis and incidence of hip fracture in women-secular trends over 30 years. BMC Musculoskelet Disord 11: pp. 1-7
  6. Osteoporosis Australia. 2004. http://www.osteoporosis.org.au
  7. Rohr, UD (2002) The impact of testosterone imbalance on depression and women’s health. Maturitas 41: pp. S25-46 CrossRef
  8. Parves, T (2004) Postmenopausal osteoporosis. JK-Practitioner 11: pp. 281-3
  9. Jilka, RL (1998) Cytokines, bone remodelling and estrogen deficiency. Bone 23: pp. 75-81 CrossRef
  10. Pfeilschifter, J, Koditz, R, Pfohl, M, Schatz, H (2002) Changes in proinflammatory cytokine activity after menopause. Endocrinol Rev 23: pp. 90-119 CrossRef
  11. Bart, C (2008) Normal bone anatomy & physiology. Clin J Am Soc Nephrol 3: pp. S131-9 CrossRef
  12. Iain, HK (2001) Principles of bone healing. Neurosurg Focus 10: pp. 1-8
  13. Khastgir, G, Studd, J, Holland, N (2001) Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: Histomorphometric evidence in a longitudinal study. J Clin Endocrinol Metabol 86: pp. 289-95
  14. Shumaker, SA, Legault, C, Rapp, R, Thal, L, Wallace, RB, Ockene, JK (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory: a randomized controlled trial. JAMA 289: pp. 2651-62 CrossRef
  15. Al-Azzawi, F (2008) Prevention of postmenopausal osteoporosis and associated fractures: Clinical evaluation of the choice between estrogen and bisphosphonates. Gynecol Endocrinol 24: pp. 601-9 CrossRef
  16. Komm, BS, Chines, AA (2010) An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis. Maturitas 71: pp. 221-6 CrossRef
  17. Cano, A, Dapia, S, Noguela, J, Pineda, B, Hermenegildo, C, Val, R (2008) Comparative effects of 17β-estradiol, raloxifene and genistein on bone 3D mircroarchitecture and volumetric bone mineral density in ovariectomized mice. Osteoporos Int 19: pp. 793-800 CrossRef
  18. Roussow, JE, Anderson, GL, Prentice, RL, LaCroix, A, Kooperberg, C, Stefanick, ML (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288: pp. 321-33 CrossRef
  19. Wassertheil-Smoller, S, Hendrix, SL, Limacher, M (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA 289: pp. 2673-84 CrossRef
  20. Chleb
• 刊物主题：Complementary & Alternative Medicine; Internal Medicine; Chiropractic Medicine;
• 出版者：BioMed Central
• ISSN：1472-6882

文摘

Background Post-menopausal osteoporosis has long been treated and prevented by estrogen replacement therapy (ERT). Despite its effectiveness, ERT is associated with serious adverse effects. Labisia pumila var. alata (LP) is a herb with potential as an alternative agent to ERT due to its phytoestrogenic, antioxidative and anti-inflammatory effects on bone. This study aimed to determine the effects of LP supplementation on bone biomechanical strength of postmenopausal osteoporosis rat model. Methods Ninety-six female Sprague–Dawley rats aged 4 to 5?months old were randomly divided into six groups; six rats in the baseline group (BL) and eighteen rats in each group of; Sham- operated (Sham), ovariectomised control (OVXC) and ovariectomised with daily oral gavages of Premarin at 64.5?μg/kg (ERT), LP at 20?mg/kg (LP20) and LP at 100?mg/kg (LP100) respectively. These groups were subdivided into three, six and nine weeks of treatment periods. Rats in BL group were euthanized before the start of the study, while other rats were euthanized after completion of their treatments. Femora were dissected out for biomechanical strength analysis using Instron Universal Model 5848 Micro Tester. Results OVXC group showed deterioration in the bone biomechanical strength with time. Both ERT and LP supplemented rats showed improvements in bone strength parameters such as maximum load, displacement, stiffness, stress, and Young Modulus. The most improved bone strength was seen in rats given LP at the dose of 100?mg/kg for nine weeks. Conclusion LP supplementation at 100?mg/kg was more effective than ERT in reversing ovariectomy-induced bone biomechanical changes.